On 21 October 2016 we delivered our predictions for the main
Industrial Property figures for the end of 2016 in Spain and the
figures filed before international bodies such as the OHIM and WIPO
In them, we published our statistical forecast, and, although it
is wise to wait for the data to be
"confirmed"1, what we can safely predict is
that the data will not vary greatly compared to the projection we
provided in October, specifically by -0.25%.
The first provisional official data
published2, unfortunately indicate that
the main milestones that we set out at the time will be
confirmed, and some indicators will even worsen slightly.
These include international, non-European-type
indicators3 or those of applications under commercial
names, the latter being especially worrisome since it tends to have
a close relationship with national company-creation indicators. We
hope it is only circumstantial.
As in the previous studies, a particularly troubling fact must
be highlighted: never in the history of the "modern
patent in Spain" have so few Spanish patents been applied for
per capita. Last year we correctly predicted that the
"baseline" of 3,0004 national patents applied
for would be lost and this year the same prediction is reiterated.
However, it seems that we may have finally bottomed out at
around 2,800 patents...
The moving average of monthly percentage changes of
year-on-year applications applied for. As we can see it gets closer
to 0, which shows the downward trend and lower
... whilst waiting to see what the New Patent Law may
bring, which we must remember will come into effect on 1 April
In this regard, if we link each type with the technological
level of the nature of innovation carried out and the level of
internationalisation of the specific figure chosen, as well as the
evolution that we predict for 2016 with the general trend of the
Spanish economy, we could draw the following table.
Types of technical innovation carried out and the
level of internationalisation shown in the figure. Those in red we
predict will have considerably worse development (negative rates)
at the end of 2016 than the development of Spanish GDP. In orange
are those that have done worse and in green are those that have
In light of the diagram, we can say that Spain is
innovative but we may be falling behind in more high-tech
Furthermore, the international, non-European indicators
and the sudden fall in the aforementioned trade names in Spain are
worrisome, due to their close relationship to other indicators,
especially economic ones.
Therefore, we will specifically monitor the data that arise over
the coming weeks and incorporate various analyses that we hope will
be of interest.
 In the case of the SPTO, there is always a
technical adjustment during the coming weeks. Considering the
adjustment of other years, we have incorporated it in the following
 In the case of the SPTO:
En 45 minutos haremos un rápido repaso de todas las novedades relevantes que, en el mundo de la Propiedad Industrial e Intelectual, se han producido durante en el transcurso del 2016, junto a nuestra previsión de los principales hitos que nos depara este nuevo año.
Queremos que los temas propuestos sean sólo aquéllos que más les interesen. A tal fin, hemos incluido los siguientes a partir de las consultas recibidas durante este año. No obstante, estaríamos encantados de contar con sus sugerencias.
La participación de la autoridad mexicana en materia de Propiedad Industrial es crucial durante la tramitación del Registro Sanitario de un medicamento alopático.
Cada etapa del proceso de Registro Sanitario tiene directrices bien establecidas; sin embargo, las etapas que se relacionan con los derechos de Propiedad Intelectual continúan causando controversia.
Con el fin de entender la relación entre los derechos de Propiedad Intelectual y el proceso de Registro Sanitario, Clarke Modet & Cº ofrece una amplia variedad de soluciones desde el punto de vista de Propiedad Intelectual.
1.The trade mark shall not entitle the proprietor to prohibit its use in relation to goods which have been put on the market in the Community under that trade mark by the proprietor or with his consent.
The UK government has not yet invoked Article 50 of the Treaty on European Union (this is likely to happen by the end of March), and the UK's actual exit from the European Union is at least two years away.
Without doubt Malta offers significant opportunities for the generics drugs Industry and the
evidence for this lies in the pharmaceutical patenting history of the country and in its legislative
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).